Research Article
Clinical Patterns and Outcome of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease
Table 3
Treatment strategies of patients.
| Initial treatment modality | HCC on NAFLD (n = 56) | HCC on ALD (n = 173) | HCC on HBV (n = 393) | value |
| TACE, n (%) | 28 (50.0%) | 112 (64.7%) | 216 (55%) | 0.027 | Surgical resection, n (%) | 11 (19.6%) | 12 (6.9%) | 56 (14.2%) | 0.014 | RFA, n (%) | 0 (0.0%) | 13 (7.5%) | 23 (5.9%) | 0.111 | Sorafenib, n (%) | 9 (16.1%) | 6 (3.5%) | 37 (9.4%) | 0.006 | Best supportive care, n (%) | 8 (14.3%) | 30 (17.3%) | 61 (15.5%) | 0.811 |
|
|
HCC: hepatocellular carcinoma; NAFLD: nonalcoholic fatty liver disease; ALD: alcoholic liver disease; HBV: hepatitis B virus; TACE: transcatheter arterial chemoembolization; RFA: radiofrequency ablation.
|